Physician

Garrett White, M.D.

According to 2025 Medicare claims, Garrett White, M.D. (NPI: 1225031842) practices nephrology in the Savannah, GA market, with the plurality of this provider's patient population coming from Chatham, GA. This provider's primary affiliated billing organization is PRIVIA MEDICAL GROUP OF GEORGIA LLC (NPI: 1013313857; TIN: 202265068) and primary practice location at 31406-3928. White is affiliated with the Privia Quality Network of Georgia (ACO ID: A3236), participating under the MSSP model.

White's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 794 traditional Medicare patients, billed 11,085 HCPCS/CPT codes, and received $406,653 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 5,691 prescription claims across 855 beneficiaries totaling $1,731,599 in drug costs, led by Tolvaptan (Tolvaptan). DME data shows 85 claims. Open Payments data shows 92 records totaling $1,886. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $202,779 to $1,731,599. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	695	6,156	$305,131
2016	911	6,824	$372,040
2017	1,033	8,309	$476,200
2018	964	7,909	$449,188
2019	1,022	8,126	$463,746
2020	1,007	7,606	$459,316
2021	931	7,823	$427,034
2022	829	8,563	$388,541
2023	774	8,593	$385,263
2024	794	11,085	$406,653

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	228	1,880	$202,779
2016	347	3,552	$411,869
2017	441	4,276	$580,622
2018	488	4,368	$482,737
2019	549	4,152	$1,022,374
2020	579	3,701	$1,234,503
2021	606	3,687	$857,757
2022	627	4,069	$824,007
2023	709	4,892	$1,203,895
2024	855	5,691	$1,731,599

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	27	$458
2017	N/R	165	$40,024
2018	N/R	101	$5,417
2019	N/R	146	$4,074
2020	N/R	151	$4,146
2021	N/R	154	$4,555
2022	N/R	115	$7,400
2023	N/R	13	$163
2024	N/R	85	$2,829

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	467	1,047	$85
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	492	1,398	$12
36415	Insertion of needle into vein for collection of blood sample	245	687	$9
80069	Kidney function blood test panel	226	641	$8
82570	Creatinine level to test for kidney function or muscle injury	219	512	$5

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Tolvaptan	Tolvaptan	51	1,751	$320,469
Farxiga	Dapagliflozin Propanediol	265	12,950	$240,959
Rayaldee	Calcifediol	95	3,030	$127,808
Kerendia	Finerenone	128	5,710	$122,038
Ozempic	Semaglutide	86	3,732	$116,234

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7518	Mycophenolic acid, oral, 180 mg	N	N/R	16	$1,098
J7515	Cyclosporine, oral, 25 mg	N	N/R	11	$826
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	26	$470
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	20	$251
J7517	Mycophenolate mofetil, oral, 250 mg	N	N/R	12	$183

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	92	$1,886	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Garrett White, M.D.?

Tedicare shows public-source Medicare data for Garrett White, M.D. (NPI 1225031842), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Garrett White, M.D. have ACO affiliation data?

Garrett White, M.D. is shown with ACO affiliation data for Privia Quality Network of Georgia (MSSP, ACO ID A3236).

What billing organization is linked to Garrett White, M.D.?

Garrett White, M.D. is linked to PRIVIA MEDICAL GROUP OF GEORGIA LLC (billing NPI 1013313857) in the available physician profile data.

Does Garrett White, M.D. have Open Payments data?

Garrett White, M.D. has 92 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.